136 related articles for article (PubMed ID: 33201456)
1. Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma.
Lee TC; Wima K; Morris MC; Johnston ME; Shah SA; Ahmad SA; Patel SH; Wilson GC
J Gastrointest Surg; 2021 Jan; 25(1):36-47. PubMed ID: 33201456
[TBL] [Abstract][Full Text] [Related]
2. Trends in the use of evidence-based therapy for resectable gastric cancer.
Snyder RA; Penson DF; Ni S; Koyama T; Merchant NB
J Surg Oncol; 2014 Sep; 110(3):285-90. PubMed ID: 24891231
[TBL] [Abstract][Full Text] [Related]
3. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
[TBL] [Abstract][Full Text] [Related]
5. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
6. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
7. Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer.
Karagkounis G; Squires MH; Melis M; Poultsides GA; Worhunsky D; Jin LX; Fields RC; Spolverato G; Pawlik TM; Votanopoulos KI; Levine EA; Schmidt C; Bloomston M; Cho CS; Weber S; Masi A; Berman R; Pachter HL; Staley CA; Newman E; Maithel SK; Hatzaras I
J Gastrointest Surg; 2017 Dec; 21(12):1984-1992. PubMed ID: 28963709
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
[TBL] [Abstract][Full Text] [Related]
9. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
[TBL] [Abstract][Full Text] [Related]
10. Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study.
Jabo B; Selleck MJ; Morgan JW; Lum SS; Bahjri KA; Aljehani M; Garberoglio CA; Reeves ME; Namm JP; Solomon NL; Luca F; Dyke C; Senthil M
J Gastrointest Oncol; 2018 Feb; 9(1):35-45. PubMed ID: 29564169
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer.
Anderson E; LeVee A; Kim S; Atkins K; Guan M; Placencio-Hickok V; Moshayedi N; Hendifar A; Osipov A; Gangi A; Burch M; Waters K; Cho M; Klempner S; Chao J; Kamrava M; Gong J
JAMA Netw Open; 2021 Dec; 4(12):e2138432. PubMed ID: 34889947
[TBL] [Abstract][Full Text] [Related]
12. Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit.
Schouwenburg MG; Busweiler LAD; Beck N; Henneman D; Amodio S; van Berge Henegouwen MI; Cats A; van Hillegersberg R; van Sandick JW; Wijnhoven BPL; Wouters MWJ; Nieuwenhuijzen GAP;
Eur J Surg Oncol; 2018 Apr; 44(4):532-538. PubMed ID: 29439836
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study.
Yeh JM; Tramontano AC; Hur C; Schrag D
Gastric Cancer; 2017 Sep; 20(5):811-824. PubMed ID: 28205057
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond.
Choi AH; Kim J; Chao J
World J Gastroenterol; 2015 Jun; 21(24):7343-8. PubMed ID: 26139980
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.
de Steur WO; van Amelsfoort RM; Hartgrink HH; Putter H; Meershoek-Klein Kranenbarg E; van Grieken NCT; van Sandick JW; Claassen YHM; Braak JPBM; Jansen EPM; Sikorska K; van Tinteren H; Walraven I; Lind P; Nordsmark M; van Berge Henegouwen MI; van Laarhoven HWM; Cats A; Verheij M; van de Velde CJH;
Ann Oncol; 2021 Mar; 32(3):360-367. PubMed ID: 33227408
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis.
Choi M; Ishizawa S; Kraemer D; Sasson A; Feinberg E
Eur J Surg Oncol; 2022 Feb; 48(2):403-410. PubMed ID: 34446344
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
19. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
20. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
